<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">73699</article-id><article-id pub-id-type="doi">10.7554/eLife.73699</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>Engineered natural killer cells impede the immunometabolic CD73-adenosine axis in solid tumors</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-254679"><name><surname>Chambers</surname><given-names>Andrea Marie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-254680"><name><surname>Lupo</surname><given-names>Kyle Byrnes</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-254681"><name><surname>Wang</surname><given-names>Jiao</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-254688"><name><surname>Cao</surname><given-names>Jingming</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-254686"><name><surname>Utturkar</surname><given-names>Sagar</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-254685"><name><surname>Atallah Lanman</surname><given-names>Nadia</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-254689"><name><surname>Bernal-Crespo</surname><given-names>Victor</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-254684"><name><surname>Jalal</surname><given-names>Shadia</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="par-6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-254687"><name><surname>Pine</surname><given-names>Sharon R</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-254683"><name><surname>Toregrosa-Allen</surname><given-names>Sandra</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-254682"><name><surname>Elzey</surname><given-names>Bennett D</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-252633"><name><surname>Matosevic</surname><given-names>Sandro</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5118-2455</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Department of Industrial and Physical Pharmacy</institution>, <institution>Purdue University West Lafayette</institution>, <addr-line><named-content content-type="city">West Lafayette</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Center for Cancer Research</institution>, <institution>Purdue University West Lafayette</institution>, <addr-line><named-content content-type="city">West Lafayette</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution content-type="dept">Histology Research Laboratory</institution>, <institution>Purdue University West Lafayette</institution>, <addr-line><named-content content-type="city">West Lafayette</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><institution content-type="dept">Department of Medicine</institution>, <institution>Indiana University</institution>, <addr-line><named-content content-type="city">Indianapolis</named-content></addr-line>, <country>United States</country></aff><aff id="aff5"><institution content-type="dept">Rutgers Cancer Institute of New Jersey</institution>, <institution>Rutgers, The State University of New Jersey</institution>, <addr-line><named-content content-type="city">New Brunswick</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-83106"><name><surname>Campbell</surname><given-names>Kerry</given-names></name><role>Reviewing editor</role><aff><institution>Fox Chase</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>sandro@purdue.edu</email> (SM);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>11</day><month>07</month><year>2022</year></pub-date><volume>11</volume><elocation-id>e73699</elocation-id><history><date date-type="received"><day>07</day><month>09</month><year>2021</year></date><date date-type="accepted"><day>10</day><month>07</month><year>2022</year></date></history><permissions><copyright-statement>Â© 2022, Chambers et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Chambers et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-73699-v1.pdf"/><abstract><p>Immunometabolic reprogramming due to adenosine produced by CD73 (encoded by the 5'-ectonucleotidase gene <italic>NT5E</italic>) is a recognized immunosuppressive mechanism contributing to immune evasion in solid tumors. Adenosine is not only known to contribute to tumor progression, but it has specific roles in driving dysfunction of immune cells, including natural killer (NK) cells. Here, we engineered human NK cells to directly target the CD73-adenosine axis by blocking the enzymatic activity of CD73. In doing so, the engineered NK cells not only impaired adenosinergic metabolism driven by the hypoxic uptake of ATP by cancer cells in a model of non-small-cell lung cancer, but also mediated killing of tumor cells due to the specific recognition of overexpressed CD73. This resulted in a 'single agent' immunotherapy that combines antibody specificity, blockade of purinergic signaling, and killing of targets mediated by NK cells. We also showed that CD73-targeted NK cells are potent <italic>in vivo</italic> and result in tumor arrest, while promoting NK cell infiltration into CD73<sup>+</sup> tumors and enhancing intratumoral activation.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001368</institution-id><institution>V Foundation for Cancer Research</institution></institution-wrap></funding-source><award-id>#D2019-039</award-id><principal-award-recipient><name><surname>Matosevic</surname><given-names>Sandro</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution>Lilly Graduate Fellowship</institution></institution-wrap></funding-source><award-id>2019</award-id><principal-award-recipient><name><surname>Chambers</surname><given-names>Andrea Marie</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001377</institution-id><institution>Walther Cancer Foundation</institution></institution-wrap></funding-source><award-id>0186.01</award-id><principal-award-recipient><name><surname>Matosevic</surname><given-names>Sandro</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution>Migliaccio/Pfizer Graduate Fellowship</institution></institution-wrap></funding-source><award-id>2019-2020</award-id><principal-award-recipient><name><surname>Chambers</surname><given-names>Andrea Marie</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>P30 CA023168</award-id><principal-award-recipient><name><surname>Utturkar</surname><given-names>Sagar</given-names></name><name><surname>Atallah Lanman</surname><given-names>Nadia</given-names></name><name><surname>Toregrosa-Allen</surname><given-names>Sandra</given-names></name><name><surname>Elzey</surname><given-names>Bennett D</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>P30 CA082709</award-id><principal-award-recipient><name><surname>Jalal</surname><given-names>Shadia</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols  of Purdue University (protocol 1112000342). All surgery was performed under sodium pentobarbital anesthesia, and every effort was made to minimize suffering.</p></fn><fn fn-type="other"><p>Human subjects: Written informed consent was obtained from all subjects involved in the study. All procedures performed in studies involving human participants were approved by Purdue University's Institutional Review Board (IRB). The peripheral blood NK cells were obtained from normal healthy donor volunteers who gave written consent through Purdue University's IRB protocol (#1804020540).</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analyzed during this study are included in the manuscript and supporting files, or are available at doi.org/10.5061/dryad.931zcrjnp. Source data have been provided for Figure 1 - Source Data 1 and 2 (Tables S1 and S2).</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Matosevic S</collab><collab>et al</collab></person-group><year iso-8601-date="2022">2022</year><source>Data from: Engineered natural killer cells impede the immunometabolic CD73-adenosine axis in solid tumors</source><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.5061/dryad.931zcrjnp">http://dx.doi.org/10.5061/dryad.931zcrjnp</ext-link><comment>Dryad Digital Repository, doi:10.5061/dryad.931zcrjnp</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-73699-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>